Part,  Chapter, Paragraph

 1    I,     2. 10.  2| biomarker discovery, and uses in oncology and cardiovascular medicine.
 2   II,     5.  3.Acr|     European Society for Medical Oncology~EUROCHIP~European Cancer
 3   II,     5.  3.Acr|         Expectancy~MOSES~Medical Oncology Status in Europe Survey~
 4   II,     5.  3.  2|     European Society for Medical Oncology (ESMO) addresses global
 5   II,     5.  3.  2|   performed the ‘MOSES’ (Medical Oncology Status in Europe Survey)
 6   II,     5.  3.  2|      about the status of medical oncology in Europe through questionnaires.
 7   II,     5.  3.  7|   differences in the teaching of oncology (particularly, medical oncology)
 8   II,     5.  3.  7|  oncology (particularly, medical oncology) and the current situation
 9   II,     5.  3.  7|          organization of medical oncology in the different countries
10   II,     5.  3.  7|        to specialists in medical oncology.~· The role of the medical
11   II,     5.  3.  7|          into the larger medical oncology community.~ ~The report
12   II,     5.  3.  9|         EUROCARE-4 study. Lancet Oncology 8 (9):773-783.~ ~Boyle P,
13   II,     5.  3.  9|             ESMO (2006): Medical Oncology Status in Europe Survey (
14   II,     5.  3.  9|          EUROCARE-4 data. Lancet Oncology 8 (9): 784-796.~ ~WCRF (
15   II,     9.  3.  1|     EUROCARE-4 data." The Lancet Oncology 8(9): 784-796.~ ~Verlato
16  III,    10.  2.  1|        version (2003). Annals of Oncology; 14: 9731005. Available
17   IV,    11.  1.  5|       For instance, the surgical oncology and general surgery intensive-care
18   IV,    11.  6.  5|  clinical practice guidelines in oncology using the Appraisal of Guidelines
19   IV,    13.  7.  3|          the fields of genomics, oncology, cardiovascular medicine,